Argenx receives review from FDA for VYVGART in seronegative gMG
14th January 2026 Uncategorised 0
Regulator accepts supplemental application supported by positive phase 3 data

More: Argenx receives review from FDA for VYVGART in seronegative gMG
Source: News
